Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cancer patients report more memory lapses, study finds

NCT ID NCT03975959

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at memory complaints in 426 people, including those with brain tumors, breast cancer, and healthy volunteers. Participants filled out questionnaires about their memory, mood, and fatigue. The goal was to understand how cancer and its treatments might affect everyday memory, especially the ability to remember future tasks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify new targets for psychological support to improve memory complaints in cancer patients.
What could go wrong
This is an observational study, not a treatment trial. It only measures subjective complaints, so it may not lead to direct improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

426 people

The number who actually took part.

Started

May 2019

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All the participants must fulfill all the following criteria to be eligible for study entry: * Be aged of 18 to 80 years old * Have a ECOG Performance Status ≤ 2 or a Karnofsky index ≥ 50 % * Have a satisfactory level of French * Have signed the informed consent Also, for the DLGG group, the patients must: * Have a histologically-proven diagnosis of DLGG (i.e., WHO grade II glioma) * Receive or have received a first oncological treatment after surgery (chemotherapy, radiation therapy…) Also, for the GB group, the patients must: \- Have a histologically-proven diagnosis of GB (i.e., WHO grade IV glioma). Also, for the breast cancer group, the patients must: \- Have a histologically-proven diagnosis of breast cancer diagnosed \< 2 years. Exclusion Criteria: Participants presenting with any of the following exclusion criteria will not be included in the study: * Patients with brain metastases * Patients under tutorship or curatorship or protective measures * Patients suffering from sensorial or motor deficits avoiding the tests administration * Patients with a reported history of psychiatric disease (e.g., mental retardation, psychotic disorders, learning disabilities, attention-deficit/hyperactivity disorder, and bipolar disorder) * Have reported a substance dependence within the past six months (e.g., cocaine or methamphetamine dependence) * Pregnant women * Legal incapacity or physical, psychological social or geographical status interfering with the patient's ability to sign the informed consent or to terminate the study Also, for the DLGG group, the patients must not: * Have an anaplastic glioma (i.e., WHO grade III glioma) * Have a DLGG with radiological or histological signs of anaplastic transformation * Have a history of HIV * Have a history of other cancer Also, for the GB group, the patients must not: * Patients treated with ≥2 lines of systemic cancer treatment (e.g., patient after the first GB recurrence) * Have a history of HIV * Have a history of other cancer Also, for the breast cancer group, the patients must not: * Have a metastatic disease * Have a neoadjuvant therapy * Have a documented neurological, or substance use disorders. * Have a history of HIV * Have a history of other cancer * Have reported a history of neurological diagnoses (e.g., seizure disorders, closed head injuries with loss of consciousness greater than 15 min). Also for the control group, the participants must not: * Have a documented neurological, or substance use disorders * Have a history of cancer * Have a history of HIV

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU D'amiens

    Amiens, Nord, 80080, France

  • CHU Lyon

    Saint-Genis-Laval, 69230, France

  • Hopital saint Louis

    Paris, 75010, France

  • Hôpital d'Instruction des Armées

    Clamart, 92190, France

  • Icm Val D'Aurelle

    Montpellier, Herault, 34298, France

  • UFR de Psychologie Université de Lille

    Villeneuve-d'Ascq, NORD, 59653, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.